686VPThorough QT study on the effect of therapeutic and supratherapeutic dosing of givinostat in healthy volunteers
Tracey Willis(Robert Jones and Agnes Hunt Orthopaedic Hospital), S. Cazzaniga(Italfarmaco (Italy)), J. Bourke(Newcastle upon Tyne Hospitals NHS Foundation Trust), Ulrike Schara‐Schmidt(University of Duisburg-Essen), Thierry Le Tourneau, O. Boespflug-Tanguy(Université Paris Cité), M. Guglieri, N. Muelas(Hospital Universitari i Politècnic La Fe), Suraya Diaz(Hospital Sant Joan de Déu Barcelona), H. Phan(Rare Disease Therapeutics (United States)), E. Niks(Leiden University Medical Center), B. Bryne(Institute of Child Health), E. Mercuri(Agostino Gemelli University Polyclinic)
Cited by 0
Related Papers
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Neurology|2024|128
Newborn screening for spinal muscular atrophy: Anticipating an imminent need
|Seminars in Perinatology|2015|79
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy
|Neurology|2023|74
The Survival of Motor Neuron Protein Acts as a Molecular Chaperone for mRNP Assembly
|Cell Reports|2017|71